<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03410953</url>
  </required_header>
  <id_info>
    <org_study_id>IBS-VACANTIB-1701</org_study_id>
    <secondary_id>2016-004991-23</secondary_id>
    <secondary_id>GRS1360/A/16</secondary_id>
    <secondary_id>17/1311</secondary_id>
    <nct_id>NCT03410953</nct_id>
  </id_info>
  <brief_title>Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines</brief_title>
  <official_title>Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Biomédica de Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Clinical Research Networt (SCReN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Health workers with biological risk in their tasks, who have been vaccinated as&#xD;
      non-responders to conventional vaccination against Hepatitis B. To provide Health&#xD;
      workers-staff with an additional protection tool against hepatitis B infection. To evaluate&#xD;
      the efficacy of the adjuvanted vaccine in healthy nonresponders to conventional hepatitis B&#xD;
      vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An interventional, phase 4, single group assignment, without masking (open label), preventive&#xD;
      clinical trial was carried out in health workers with biological risk in their tasks, who&#xD;
      have been filed as non-responders to conventional vaccination against Hepatitis B.&#xD;
&#xD;
      Methods: 67 health workers with biological risk in their tasks, who have been filed as&#xD;
      non-responders to conventional vaccination against Hepatitis B, were enrolled in the Clinical&#xD;
      Trial. All participants were from 18 years up to 64 years old. The criteria defining them as&#xD;
      non-responders to the conventional hepatitis B vaccine is anti HBsAb titers &lt; 10 mUI/ml&#xD;
      following the application of six doses of conventional vaccine at 20 lg doses (two complete&#xD;
      guidelines). The objective of this study was to provide Health workersstaff with an&#xD;
      additional protection tool against hepatitis B infection, and to evaluate the efficacy of the&#xD;
      adjuvanted vaccine in healthy non-responders to conventional hepatitis B vaccine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2018</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>non-responders to conventional treatment of hepatitis B vaccination and consent to participate</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Protective Levels of Antibodies After Treatment</measure>
    <time_frame>Between 40 and 60 days after the last dose given</time_frame>
    <description>Measurement of antibody antiHBs: before the first dose and a month after the administration of each dose.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis</condition>
  <condition>Hepatitis, Viral, Human</condition>
  <condition>Hepatitis B Immunization</condition>
  <arm_group>
    <arm_group_label>Fendrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:&#xD;
1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).</intervention_name>
    <description>The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:&#xD;
1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine</description>
    <arm_group_label>Fendrix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NHS workers -including university students doing their internships in health centres&#xD;
             dependent on the National Health System (inclusion of students is regulated and&#xD;
             limited by specific instructions on labour prevention in each autonomous community).&#xD;
&#xD;
          -  Criteria defining them as NO responders to the conventional hepatitis B vaccine: anti&#xD;
             HBsAb titers &lt;10 mIU / ml following the application of six doses of conventional&#xD;
             vaccine at 20 μg doses (two complete guidelines).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to the active substance or any of the other ingredients of the medicinal&#xD;
             product (included in section 6 of the product data sheet).&#xD;
&#xD;
          -  Subjects that have ever had an allergic reaction to any vaccine against hepatitis B.&#xD;
&#xD;
          -  Subjects have a serious infection with fever.&#xD;
&#xD;
          -  Subjects for whom informed consent is not obtained.&#xD;
&#xD;
          -  Subjects that have not revoked the consent initially signed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose L. Bravo-Grande, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IBSAL-Instituto de Investigación Biomédica de Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de León</name>
      <address>
        <city>León</city>
        <zip>24080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Palencia</name>
      <address>
        <city>Palencia</city>
        <zip>34005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial de Zamora</name>
      <address>
        <city>Zamora</city>
        <zip>49022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2018</study_first_posted>
  <results_first_submitted>January 21, 2021</results_first_submitted>
  <results_first_submitted_qc>July 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2021</results_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Viral, Human</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03410953/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03410953/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fendrix</title>
          <description>The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:&#xD;
1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine&#xD;
Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).: The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:&#xD;
1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67">First patient recruited</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67">67 participants were enrolled in the Clinical Trial and included the analyses</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects had to work in the SNS -including university students undertaking work placements in SNS health centres (subject to and limited by the specific regulations on health and safety in each autonomous region)- and be of working age.</population>
      <group_list>
        <group group_id="B1">
          <title>Fendrix</title>
          <description>The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:&#xD;
1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine&#xD;
Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).: The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:&#xD;
1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.46" spread="11.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Protective Levels of Antibodies After Treatment</title>
        <description>Measurement of antibody antiHBs: before the first dose and a month after the administration of each dose.</description>
        <time_frame>Between 40 and 60 days after the last dose given</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fendrix</title>
            <description>The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:&#xD;
1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine&#xD;
Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).: The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:&#xD;
1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Protective Levels of Antibodies After Treatment</title>
          <description>Measurement of antibody antiHBs: before the first dose and a month after the administration of each dose.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 6 months</time_frame>
      <desc>AE 32 SAE 0 Total 32</desc>
      <group_list>
        <group group_id="E1">
          <title>Fendrix</title>
          <description>The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:&#xD;
1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine&#xD;
Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).: The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:&#xD;
1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Paresthesia in the puncture area</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cramp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Puncture Zone Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Number of possible participants from all hospitals were small. This resulted in the need to extend recruitment to additional centres in order to obtain an optimal study sample.&#xD;
We also encountered a lack of information concerning staff who do not respond to vaccination.&#xD;
We also encountered some isolated difficulties as regards organizing all trial visits and their dates for various reasons, including vacations and sick leave. It was resolved through study coordination.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ricardo López-Pérez, PhD. Study Coordinator and Manager of Clinical Trial</name_or_title>
      <organization>UICEC, Complejo Asistencial Universitario de Salamanca - Instituto de Investigación Biomédica de Salamanca (IBSAL), Plataforma SCReN, Salamanca, Spain</organization>
      <phone>923 291100 ext 55779</phone>
      <email>ricardo.lopez@scren.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

